Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Takeda Pharmaceutical
Deal Size : $372.5 million
Deal Type : Collaboration
Treventis Partners its Preclinical Program in Alzheimer's Disease with Takeda
Details : Under the terms of the agreement, Takeda will have an option to exclusively license the program worldwide for the development and commercialization of small molecules that target tau, a key protein in Alzheimer's Disease (AD).
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 04, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Takeda Pharmaceutical
Deal Size : $372.5 million
Deal Type : Collaboration